These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 31081793)
1. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. Hauser RA; Kremens DE; Elmer LW; Kreitzman DL; Walsh RR; Johnson R; Howard R; Nguyen JT; Patni R J Parkinsons Dis; 2019; 9(3):591-600. PubMed ID: 31081793 [TBL] [Abstract][Full Text] [Related]
2. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122 [TBL] [Abstract][Full Text] [Related]
12. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D; Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Pajo AT; Espiritu AI; Jamora RDG Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922 [No Abstract] [Full Text] [Related]
14. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533 [TBL] [Abstract][Full Text] [Related]
15. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses. Pahwa R; Aldred J; Gupta N; Terasawa E; Garcia-Horton V; Steffen DR; Kandukuri PL; Chaudhari VS; Jalundhwala YJ; Bao Y; Kukreja P; Isaacson SH Neurol Ther; 2022 Jun; 11(2):711-723. PubMed ID: 35192177 [TBL] [Abstract][Full Text] [Related]
16. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720 [TBL] [Abstract][Full Text] [Related]
17. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546 [TBL] [Abstract][Full Text] [Related]
18. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis. LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286 [TBL] [Abstract][Full Text] [Related]
19. Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia. Hauser RA; Zeitlin L; Fisher S; D'Souza R J Parkinsons Dis; 2020; 10(3):915-925. PubMed ID: 32568108 [TBL] [Abstract][Full Text] [Related]
20. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]